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Background
Endothelial dysfunction is supposed to be a key event in
the development of several cardiovascular diseases. In the
middle-aged, apparently healthy population, the
endothelial function is frequently already impaired, repre-
senting the first step in the development of cardiovascular
diseases. It seems reasonable to try to improve endothelial
dysfunction in the mentioned population also by phar-
macological approaches. It can be assumed that therapies
that could improve the function of the vascular endothe-
lium would lead to diminishing or slowing the onset of
cardiovascular diseases. The aim of our study was to eval-
uate the protective pleiotropic effects of a combination of
statin and angiotensin receptor blocker at sub-therapeutic
doses in middle-aged volunteers with low risk for cardio-
vascular disease on the function of endothelium.
Methods
Ten healthy volunteers (males) aged from 30 to 50 years
without history of cardiovascular disease, diabetes melli-
tus, hypertension or hypercholesterolemia were recruited
for the study. Subjects took a combination of statin (fluv-
astatin 10 mg) and angiotensin receptor blocker (valsar-
tan 20 mg) daily for 30 days. Ultrasound measurements
(Aloka Alfa 10 ProSound echo-machine) of flow-medi-
ated dilatation (FMD) were repeated three times: at the
beginning of the study, after 14 days, and at the end of the
study. FMD was measured on the right brachial artery after
reactive hyperemia, which was induced by inflation of a
pneumatic blood pressure cuff placed around the widest
part of the forearm to a systolic pressure of 190 mmHg for
4 minutes. Blood samples were taken at the beginning and
at the end of the study in order to make laboratory meas-
urements.
Results
In almost all subjects involved in or study (9 out of 10)
FMD was initially impaired. FMD was significantly
improved at the end of the study compared to values at
the beginning of the study (3.98 ± 0.43% vs. 5.87 ±
0.72%; p < 0.01). The values of diastolic blood pressure
were significantly lower at the end of the study (83.2 ± 7.4
mmHg vs. 71.1 ± 7.0 mmHg; p < 0.05). The combination
of the drugs used in the study did not affect serum choles-
terol levels.
Conclusion
In middle-aged healthy volunteers exposed to a combina-
tion of sub-therapeutic doses of fluvastatin and valsartan
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for 30 days, endothelium-dependent vasodilation was sig-
nificantly improved.